Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity in a research report issued to clients and investors on Tuesday. They presently have a $22.00 price target on the stock. Canaccord Genuity’s price target suggests a potential upside of 108.14% from the stock’s previous close.

Several other equities research analysts have also weighed in on the company. BidaskClub raised Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Zacks Investment Research raised Aquinox Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 target price on the stock in a research report on Thursday, August 10th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $28.00 target price on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 target price on shares of Aquinox Pharmaceuticals in a research report on Thursday, November 9th. Finally, ValuEngine lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $22.50.

Aquinox Pharmaceuticals (NASDAQ AQXP) traded down $0.54 during mid-day trading on Tuesday, hitting $10.57. The company had a trading volume of 85,700 shares, compared to its average volume of 86,947. Aquinox Pharmaceuticals has a twelve month low of $10.20 and a twelve month high of $19.97.

COPYRIGHT VIOLATION WARNING: “Aquinox Pharmaceuticals, Inc. (AQXP) Earns Buy Rating from Canaccord Genuity” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/21/aquinox-pharmaceuticals-inc-aqxp-earns-buy-rating-from-canaccord-genuity.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. Alps Advisors Inc. increased its holdings in shares of Aquinox Pharmaceuticals by 4.7% during the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after purchasing an additional 939 shares during the period. Northern Trust Corp increased its holdings in shares of Aquinox Pharmaceuticals by 3.3% during the second quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after purchasing an additional 2,691 shares during the period. Bank of New York Mellon Corp increased its holdings in shares of Aquinox Pharmaceuticals by 16.5% during the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after purchasing an additional 3,299 shares during the period. Alyeska Investment Group L.P. increased its holdings in shares of Aquinox Pharmaceuticals by 1.8% during the third quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock valued at $4,010,000 after purchasing an additional 5,046 shares during the period. Finally, Archon Partners LLC increased its holdings in shares of Aquinox Pharmaceuticals by 44.0% during the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after purchasing an additional 5,500 shares during the period. 95.51% of the stock is currently owned by hedge funds and other institutional investors.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Stock Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.